Also trades as: 0JBU.L (LSE) · $vol 0M
NTLA NASDAQ
Intellia Therapeutics, Inc.
1W: -5.5%
1M: -25.4%
3M: -2.1%
YTD: +34.3%
1Y: +27.9%
3Y: -71.7%
5Y: -81.5%
$12.60
+0.23 (+1.86%)
Weekly Expected Move ±12.4%
$10
$12
$14
$15
$17
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Cash Flow Trends
Operating Cash Flow
-$349M
+0.0% ▲
Capital Expenditures
$6M
+0.0% ▲
5Y CAGR: +10.0%
Free Cash Flow
-$355M
+0.0% ▲
Dividends Paid
$0
+0.0% ▲
Buybacks
$0
+0.0% ▲
Net Change in Cash
-$38M
+0.0% ▲
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | -$268M | -$474M | -$481M | -$519M | -$519M |
| Depreciation & Amort. | $7M | $8M | $9M | $10M | $10M |
| Stock-Based Comp. | $47M | $91M | $134M | $154M | $154M |
| Change in Working Capital | -$23M | -$54M | -$52M | $12M | -$74M |
| Other Non-Cash Items | $3M | $96M | -$3M | -$6M | $79M |
| Operating Cash Flow | -$225M | -$333M | -$394M | -$349M | -$349M |
| — Investing Activities — | |||||
| Capital Expenditures | -$13M | -$58M | -$14M | -$6M | -$6M |
| Acquisitions (Net) | -$3M | -$45M | $0 | $0 | $0 |
| Investment Purchases | -$1.0B | -$429M | -$904M | -$936M | -$936M |
| Investment Sales | $486M | $648M | $887M | $1.1B | $1.0B |
| Other Investing | $0 | $45M | $0 | $0 | $21M |
| Investing Cash Flow | -$551M | $160M | -$31M | $126M | $126M |
| — Financing Activities — | |||||
| Net Debt Issuance | $0 | $0 | $0 | $0 | $0 |
| Stock Repurchased | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 |
| Other Financing | $43M | $17M | $11M | $9M | $54M |
| Financing Cash Flow | $737M | $583M | $130M | $186M | $186M |
| Net Change in Cash | -$39M | $410M | -$295M | -$38M | -$38M |
| Cash End of Period | $125M | $535M | $240M | $203M | $203M |
| Free Cash Flow | -$238M | -$392M | -$408M | -$355M | -$355M |